Revalesio Corporation
Revalesio is a clinical-stage pharmaceutical company dedicated to developing safer and more effective treatments for neurological conditions such as stroke and ALS. Their pioneering science addresses fundamental disease mechanisms to improve recovery, slow disease progression, and enhance quality of life. They focus on innovative therapies based on physics and nanotechnology, with a pipeline that includes RNS60, a potential treatment for acute ischemic stroke and neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Revalesio Corporation
Products
Investigational oxygen‑saturated saline therapeutic (nanostructure-based formulation)
An investigational therapeutic formulated as oxygen-saturated saline using a physics-based process that generates stabilized nanostructures/nanobubbles; developed for neuroprotection and to modulate mitochondrial biogenesis and inflammation. Administered intravenously or via inhalation in clinical and preclinical studies.
Investigational oxygen‑saturated saline therapeutic (nanostructure-based formulation)
An investigational therapeutic formulated as oxygen-saturated saline using a physics-based process that generates stabilized nanostructures/nanobubbles; developed for neuroprotection and to modulate mitochondrial biogenesis and inflammation. Administered intravenously or via inhalation in clinical and preclinical studies.
Services
Designing, sponsoring and collaborating on multicenter clinical trials (Phase I–II) for investigational neurological therapeutics, including protocol development, site coordination and data dissemination.
Providing investigational therapies to eligible existing patients through institutional expanded access protocols and named-patient programs while managing limited clinical supply.
Collaborative preclinical programs with academic laboratories to evaluate mechanism of action, neuroprotection, myelination, mitochondrial function and efficacy in disease models.
Business development activities to explore licensing, partnering and inclusion of investigational candidates in platform trials and consortium studies.
Designing, sponsoring and collaborating on multicenter clinical trials (Phase I–II) for investigational neurological therapeutics, including protocol development, site coordination and data dissemination.
Providing investigational therapies to eligible existing patients through institutional expanded access protocols and named-patient programs while managing limited clinical supply.
Collaborative preclinical programs with academic laboratories to evaluate mechanism of action, neuroprotection, myelination, mitochondrial function and efficacy in disease models.
Business development activities to explore licensing, partnering and inclusion of investigational candidates in platform trials and consortium studies.
Expertise Areas
- Clinical trial management (randomized, double-blind, placebo-controlled trials)
- Neuroprotective therapeutics for acute ischemic stroke
- Therapeutics for neurodegenerative diseases (ALS, Alzheimer’s, Parkinson’s, MS)
- Translational medicine (mechanism-to-clinic)
Key Technologies
- Oxygen-saturated saline formulation via stabilized nanobubbles/charge-stabilized nanostructures
- Intravenous infusion and inhalation (nebulization) delivery methods
- PI3K-related signaling pathway modulation and mitochondrial biogenesis assays
- Magnetic resonance imaging (MRI) for infarct volume quantification
News & Updates
Analysis showing RNS60's potential to reduce infarct growth and improve recovery when administered within 12 hours of stroke onset.
Further data demonstrating RNS60's safety and efficacy in reducing brain tissue loss and improving functional outcomes.
Accelerates development and review process for RNS60 as a potential ALS treatment.
Provides incentives for developing RNS60 for rare disease ALS.
Analysis showing RNS60's potential to reduce infarct growth and improve recovery when administered within 12 hours of stroke onset.
Further data demonstrating RNS60's safety and efficacy in reducing brain tissue loss and improving functional outcomes.
Accelerates development and review process for RNS60 as a potential ALS treatment.
Provides incentives for developing RNS60 for rare disease ALS.